Mometasone Furoate Global Market Report 2022: Increasing Worldwide Prevalence of Asthma Fueling Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Mometasone Furoate Market, by Dosage Form, by Indication, by Route Of Administration, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.

Mometasone furoate topical is effective at reducing the redness, itching, swelling, and other pain caused by several skin conditions. Mometasone furoate is a corticosteroid drug also used to treat asthma and it is an effective treatment for a variety of skin allergies as well as other allergic conditions like hay fever and allergic rhinitis.

Market Dynamics

Increasing prevalence of asthma worldwide is expected to witness significant growth in forecast period. For instance, according to the World Health Organization (WHO), in 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by asthma worldwide. Asthma is widely misdiagnosed and poorly managed, particularly in low- and middle-income countries. In most severe cases, asthma can be fatal.

Increasing product launches and approvals by market players are expected to drive growth of the global mometasone furoate market over the forecast period. For instance, in April 2017, Amneal Pharmaceuticals LLC, a U.S.-based, publicly traded generics and specialty pharmaceutical company launched Mometasone furoate nasal spray, the first pharmaceutical product that Amneal Pharmaceuticals LLC had produced in spray form. Nasonex is therapeutic equivalent of mometasone furoate and is offered in 50 mcg/spray strength.

Increasing research and development activities related to mometasone furoate are expected to drive growth of market over the forecast period. For instance, according to an article published in Medicine, medical journal, in December 2019, a study was performed on patients with head and neck squamous cell carcinoma (HNSCC) to check efficacy of local application of mometasone furoate in reducing acute radiation dermatitis (ARD) in China.

Patients were divided into two groups, test groups and control groups. The patients in test groups were given mometasone furoate once daily from the start of their radiotherapy until the test side skin acquired ARD lesions, and patients in control groups, were given no treatment at all. The study showed that, mometasone furoate inunction after high dose radiotherapy can prevent acute radiation dermatitis (ARD).

Key features of the study:

This report provides an in-depth analysis of the global mometasone furoate market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global mometasone furoate market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.

The global mometasone furoate market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mometasone furoate market

Detailed Segmentation:

Global Mometasone Furoate Market, By Dosage form:

Nasal Spray

Cream

Ointment

Inhalers

Others (Topical Solutions, etc.)

Global Mometasone Furoate Market, By Indication:

Inflammatory Skin Disorders

Asthma

Allergic rhinitis

Others (Hay Fever, etc.)

Global Mometasone Furoate Market, By Route of Administration:

Nasal Administration

Topical

Oral

Global Mometasone Furoate Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Mometasone Furoate Market, By Region:

North America

U.S.

Canada

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

Europe

U.K.

Germany

Italy

Spain

France

Russia

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

GCC

Israel

Rest of Middle East

Africa

South Africa

Central Africa

North Africa

Company Profiles

Cipla

Teva Pharmaceuticals

Glenmark Pharmaceuticals

AdvaCare Pharma

Medlab Pharmaceuticals Private Limited

Dermocare Laboratories

Iva Healthcare Private Limited

Unilab Chemicals & Pharmaceuticals Pvt Ltd

Organon group of companies

Cosette Pharmaceuticals

Taro Pharmaceutical Industries Ltd.

Hikma Pharmaceuticals.

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Mometasone Furoate Market – Impact of Coronavirus (Covid-19) Pandemic

5. Global Mometasone Furoate Market , By Dosage Form, 2017-2030 (US$ Million)

6. Global Mometasone Furoate Market , By Indication, 2017-2030 (US$ Million)

7. Global Mometasone Furoate Market , By Route of Administration , 2017-2030 (US$ Million)

8. Global Mometasone Furoate Market , By Distribution Channel, 2017-2030 (US$ Million)

9. Global Mometasone Furoate Market , By Region, 2017-2030 (US$ Million)

10. Competitive Landscape

11. Section

For more information about this report visit https://www.researchandmarkets.com/r/b1t97u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.